TY - JOUR
T1 - Clinicopathological features of appendiceal goblet cell adenocarcinoma in Japan
T2 - a multicenter retrospective study
AU - the Study Group of Appendiceal Neoplasms from the Japan Society of Colorectal Cancer Research Group
AU - Shiota, Tetsuya
AU - Murata, Kohei
AU - Kishimoto, Mitsuo
AU - Yao, Takashi
AU - Noura, Shingo
AU - Morita, Shunji
AU - Akiyoshi, Takashi
AU - Okamura, Shu
AU - Imasato, Mitsunobu
AU - Furuhata, Tomohisa
AU - Suto, Takeshi
AU - Takemasa, Ichiro
AU - Shingai, Tatsushi
AU - Ueda, Masami
AU - Mizuno, Hitoshi
AU - Hisamatsu, Yuichi
AU - Takeda, Takashi
AU - Fujii, Makoto
AU - Kagawa, Yoshinori
AU - Sugihara, Kenichi
N1 - Funding Information:
We thank the following doctors for their cooperation during this study: M. Ikeda (Hyogo College of Medicine), M. Itabashi (Tokyo Women’s Medical University), Y. Ide (Yao Municipal Hospital), A. Iwashita (Fukuoka University Chikushi Hospital), Y. Ohno (Osaka University), Ozawa (Tochigi Cancer Center), T. Kato (Osaka National Hospital), K. Sakamoto (Juntendo University), A. Shiomi (Shizuoka Cancer Center Hospital), Y. Takii (Niigata Cancer Center Hospital), Y. Doki (Osaka University), M. Nakanishi (Kyoto Prefectural University of Medicine), T. Mizushima (Osaka University), K. Yamazaki (Shizuoka Cancer Center Hospital), H. Yokomizo (Tokyo Women’s Medical University Medical Center East), K. Yoshimatsu (Saiseikei Kurihashi Hospital), H. Takeyama (Minoh City Hospital), M. Tsujie (Sakai City Medical Center), H. Ohta (Ikeda City Hospital), A. Ogawa (Tane General Hospital), K. Yasumasa (Japan Community Healthcare Organization Osaka Hospital), K. Tamagawa (Otemae Hospital), H. Takemoto (Kinki Central Hospital), and M. Fukunaga (Hyogo Prefectural Nishinomiya Hospital).
Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.
PY - 2023/2
Y1 - 2023/2
N2 - Purpose: In the 5th edition of the World Health Organization classification, appendiceal goblet cell adenocarcinoma (GCA) is categorized separately from neuroendocrine tumors and other appendiceal adenocarcinomas. We clarified the clinicopathological characteristics of Japanese appendiceal GCA. Methods: We designed a retrospective multicenter cohort study and retrieved the data of patients with appendiceal neoplasms and histologically diagnosed appendiceal goblet cell carcinoid (GCC) treated from January 2000 to December 2017 in Japan. The available GCC slides were reviewed and diagnosed with a new grading system of GCA. Results: A total of 922 patients from 43 institutions were enrolled; of these, 32 cases were patients with GCC (3.5%), and 20 cases were ultimately analyzed. The 5-year survival rate was 61.4% (95% confidence interval: 27.4–83.2), and the median survival time was 93.1 months. For peritoneal metastasis, regional lymph node metastasis was a significant factor (p = 0.04), and Grade 3 was a potential factor (p = 0.07). No peritoneal metastasis was observed in either T1/2 patients (n = 2) or Grade 1 patients (n = 4). We were unable to detect any significant factors associated with regional lymph node metastasis. Conclusion: For peritoneal metastasis, regional lymph node metastasis was a significant factor, and Grade 3 was a potential factor.
AB - Purpose: In the 5th edition of the World Health Organization classification, appendiceal goblet cell adenocarcinoma (GCA) is categorized separately from neuroendocrine tumors and other appendiceal adenocarcinomas. We clarified the clinicopathological characteristics of Japanese appendiceal GCA. Methods: We designed a retrospective multicenter cohort study and retrieved the data of patients with appendiceal neoplasms and histologically diagnosed appendiceal goblet cell carcinoid (GCC) treated from January 2000 to December 2017 in Japan. The available GCC slides were reviewed and diagnosed with a new grading system of GCA. Results: A total of 922 patients from 43 institutions were enrolled; of these, 32 cases were patients with GCC (3.5%), and 20 cases were ultimately analyzed. The 5-year survival rate was 61.4% (95% confidence interval: 27.4–83.2), and the median survival time was 93.1 months. For peritoneal metastasis, regional lymph node metastasis was a significant factor (p = 0.04), and Grade 3 was a potential factor (p = 0.07). No peritoneal metastasis was observed in either T1/2 patients (n = 2) or Grade 1 patients (n = 4). We were unable to detect any significant factors associated with regional lymph node metastasis. Conclusion: For peritoneal metastasis, regional lymph node metastasis was a significant factor, and Grade 3 was a potential factor.
UR - http://www.scopus.com/inward/record.url?scp=85135358568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135358568&partnerID=8YFLogxK
U2 - 10.1007/s00595-022-02562-z
DO - 10.1007/s00595-022-02562-z
M3 - Article
C2 - 35913635
AN - SCOPUS:85135358568
SN - 0941-1291
VL - 53
SP - 174
EP - 181
JO - Surgery today
JF - Surgery today
IS - 2
ER -